British Pound: Month-end rebalancing and UK policy mix – BNY
BNY's Geoff Yu notes that month-end rebalancing flows leave the British Pound (GBP) vulnerable, with GBP seen as particularly exposed after strong performance and stretched GBP/USD levels. United Kingdom (UK) assets react to Chancellor Healey’s emphasis on fiscal discipline under the Labour government, while business confidence improves and pricing intentions ease, shaping expectations for the Pound and gilts.
Pound exposure and shifting UK backdrop
"MXN stood out as the clearest carry expression, while GBP and EUR benefited from hedging flows and relatively supportive rate profiles."
"GBP looks particularly exposed given stretched GBP/USD levels and the associated earnings-translation drag, while EUR faces a similar, if slightly less acute, risk."
"U.K. Chancellor John Healey said fiscal discipline will be the bedrock of the Labour government’s first budget under Prime Minister Andy Burnham, pledging to remain within existing fiscal rules while deferring decisions on raising defense spending to 3% of GDP until next year's spending review."
"The broader policy challenge is balancing tighter fiscal constraints with growing defense and resilience demands, as the U.K. responds to higher security risks, hybrid threats and pressure to increase military preparedness without undermining confidence in the public finances."
"The U.K.’s August 2026 Lloyds’ Business Barometer showed business confidence rose 4 points to 53% in August, the highest since March and above the 12-month average of 47%."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
